January 24, 2013 at 09:33 AM EST
CORRECTION -- Biodel Reports Positive Top-Line Results From Clinical Study of Ultra-Rapid-Acting Insulin Analog Candidates

DANBURY, Conn., Jan. 24, 2013 (GLOBE NEWSWIRE) -- In a release issued earlier today by Biodel Inc. (Nasdaq:BIOD), one reference to BIOD-238 should have been BIOD-250 in the fourth paragraph. The corrected paragraph follows:

Local injection site discomfort was measured with a 100 mm visual analog scale (VAS) and patient questionnaires. 100 mm is defined as the worst possible discomfort and 0 mm is defined a having no discomfort. In the trial, the VAS score was numerically lower, but not significantly different for BIOD-250 compared to Humalog® (mean VAS scores of 2.7 mm and 8.2 mm for BIOD-250 and Humalog®, respectively; p=NS). The VAS score for BIOD-238 was significantly higher than that associated with Humalog® (mean VAS score of 24.2 mm, p=0.029 vs. Humalog®).

BIOD-G

CONTACT: Seth D. Lewis, +1-646-378-2952
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here
//-->